Advertisement
Cancer Progress and Priorities

Cancer Progress and Priorities: Uterine Cancer

Ashley S. Felix and Louise A. Brinton
DOI: 10.1158/1055-9965.EPI-18-0264 Published September 2018

This article is featured in Highlights of This Issue, p. 983

Background

Uterine corpus cancer is the most common invasive gynecologic cancer among U.S. women. Studies of endometrial cancers, which comprise approximately 90% of all uterine cancers, have identified numerous risk factors, many of which appear to reflect high levels of estrogens in the absence of sufficient progesterone. Recent advances have indicated that the disease is etiologically heterogeneous, consisting of at least two major subgroups. This heterogeneity extends to important racial differences in both incidence and survival, possibly partially attributable to genetic factors.

Descriptive Epidemiology

Uterine cancer incidence is highest in North America and Northern Europe, intermediate in Southern Europe and temperate South America, and lowest in Southern and Eastern Asia and most of Africa (Fig. 1; ref. 1). This likely reflects prevalence differences in risk factors, including obesity and reproductive patterns. In the United States, uterine cancer is the fourth most frequently diagnosed cancer, with estimates of 63,230 diagnoses in 2018 (lifetime risk of 1 out of every 40 women; ref. 2). The average annual age-adjusted incidence of uterine cancer from the Surveillance, Epidemiology and End Results Program (SEER) was 25.7 per 100,000 women between 2010 and 2014 (3). The disease is rare before the age of 45 years, but risk rises sharply among women of all races in their late 40s to middle 60s (Fig. 2). Worldwide, uterine cancer ranked in 2012 as the sixth most common cancer, with 319,600 estimated cases (4).

Figure 1.
Figure 1.

Age-standardized incidence rates for corpus uteri cancer. Figure 1 shows age-standardized incidence rates for corpus uteri cancer using data from GLOBOCAN, 2012. Uterine cancer incidence is highest in North America and Northern Europe, intermediate in Southern Europe and temperate South America, and lowest in Southern and Eastern Asia and most of Africa.

Figure 2.
Figure 2.

Age-specific uterine cancer incidence rates. Figure 2 shows age-specific uterine cancer incidence rates among non-Hispanic white, Hispanic white, black, American Indian/Alaskan Native, and Asian/Pacific Islander U.S. women using data from the SEER Program (SEER-18, 2003–2014).

Dramatic changes in the incidence of uterine cancers have occurred over time. A marked increase in U.S. incidence peaked around 1975, a trend later linked with the widespread use of menopausal estrogens in the late 1960s and early 1970s (Fig. 3). After a subsequent period of steady or declining incidence rates in many countries, endometrial cancer is again on the rise, mirroring increases in obesity prevalence (4, 5).

Figure 3.
Figure 3.

Trends in uterine cancer incidence and mortality. Figure 3 shows trends in uterine cancer incidence and mortality among white and black U.S. women using data from the SEER Program (SEER-9, 1973–2014).

In the United States, age-adjusted mortality is 4.6 per 100,000 women, whereas in Europe, mortality ranges between 2 and 4 per 100,000 (refs. 3, 6; Fig. 4). Similar to recent incidence increases, endometrial cancer mortality rates are also on the rise (4, 7). Overall, 5-year survival is approximately 82%, which represents a marked increase since the 1960s when it was 60% (8, 9). The distribution of uterine cancer stage, a strong prognostic factor, has remained stable (8, 10–12). Five-year survival is 95.3% for localized, 67.5% for regional, and 16.9% for distant-stage diseases (9).

Figure 4.
Figure 4.

Age-standardized mortality rates for corpus uteri cancer. Figure 4 shows age-standardized mortality rates for corpus uteri cancer using data from GLOBOCAN, 2012. In the United States, age-adjusted mortality is 4.6 per 100,000 women, whereas in Europe, mortality ranges between 2 and 4 per 100,000.

Disparities

Historically, endometrial cancer incidence was lower among black compared with white women; however, that gap has narrowed significantly over time (13–17). Moreover, once hysterectomy rates are taken into account, incidence in blacks surpasses that of whites (18). Although the associations for established endometrial cancer risk factors among black and white women are similar (19), prevalence differences may partially explain the markedly higher incidence increases among blacks. Endometrial cancer mortality is twice as high among black compared with white women (8.1 vs. 4.2 per 100,000 women) and has been attributed to aggressive clinical characteristics, lower socioeconomic status, higher prevalence of comorbid conditions, poor patient–provider interactions, and inferior treatment (20). Although less frequently studied, Asian and Hispanic women have lower risks of endometrial cancer compared with white women; however, 5-year survival is the same or better (17, 21).

Risk Factors

Metabolic factors

A strong risk factor for endometrial cancer is obesity, accounting for 40% to 50% of all U.S. cases (refs. 22, 23; see Table 1 and Fig. 5). Overall body size appears to be more important than body fat distribution (24). Women with obesity-associated diseases such as diabetes (25, 26), hypertension (27), and polycystic ovary syndrome (28) are also at elevated risk, although obesity may contribute to these relationships. Metabolic syndrome has also been associated with significant risk elevations, although to a lesser extent than obesity (29).

View this table:
Table 1.

Summary of risk factors, candidate genes, and serum biomarkers associated with endometrial cancer risk

Figure 5.
Figure 5.

Magnitude of association of endometrial cancer risk factors. Figure 5 contains a summary of the magnitude of association for established endometrial cancer risk factors. Risks are approximate and can vary depending on the extent of exposure.

Reproductive factors

Nulliparous women are at substantially higher risks than parous women (30, 31), with infertility additionally contributing to risk (32). Other established reproductive risk factors include young ages at menarche and/or old ages at menopause (30, 33), potentially reflecting increased numbers of lifetime ovulatory cycles (34). Breastfeeding has also recently emerged as a possible protective factor (35, 36).

Contraceptives

The use of combination oral contraceptives has been linked with marked risk reductions which persist for more than 30 years after discontinuation. Intrauterine devices also appear to reduce endometrial cancer risk (37, 38).

Menopausal hormone therapy

Menopausal hormones have been strongly linked with risk increases, particularly for extended usage of high-dose unopposed estrogens (39). Progestins cause regression of estrogen-induced endometrial hyperplasia, the presumed precursor of most endometrial cancers (40), leading to estrogens commonly being prescribed with a progestin (particularly among nonhysterectomized women). Sequential progestin use, i.e., <10 days per month, is associated with only slight risk reductions compared with unopposed estrogen use (41). However, continuous combination therapy reduces risk compared with nonhormone usage (39, 42). Associations of hormone usage are strongly modified by body mass index (BMI; refs. 39, 43).

Tamoxifen use

Clinical trials have demonstrated increased endometrial cancer risk among tamoxifen-treated breast cancer patients, with risks highest shortly after exposure, among those receiving high cumulative doses, and for histologies usually associated with a poor prognosis (44, 45).

Lifestyle factors

Cigarette smoking (46, 47) and moderate-to-active physical activity levels (48–50) have been associated with reduced risks, relations that are independent of other risk factors, including obesity.

Other factors

It remains less clear whether risk reductions associated with high levels of fruit and vegetable consumption and/or of micronutrients are independent risk factors (51–54). Higher dairy product intake (55), coffee consumption (56), and consumption of green, but not black, tea (57) may lead to risk reductions. High-fat diets (53, 54) and alcohol consumption (58) have not generally been associated with risk. Use of the antidiabetic drug metformin (59) or aspirin (60) appears to slightly reduce risk.

Controversial risk factors

Less accepted as potential risk factors are several occupational exposures (61, 62); talcum powder use (63–65); thyroid diseases, cholecystectomy and endometriosis (66–68); antidepressants, statins, and acetaminophen (69–71); endocrine disruptors (72); tubal ligation (73); and electromagnetic radiation (74).

Familial and genetic factors

Elevated endometrial cancer risks have been noted among women with a first-degree family history of endometrial cancer (75, 76). This could reflect familial obesity (genetic or environment) or inherited risk, such as Lynch syndrome, an autosomal-dominant cancer predisposition syndrome attributed to germline mutations in one of several mismatch repair genes. Specific mutations have been estimated to result in cumulative lifetime endometrial cancer risks ranging between 12% and 61% (77–81), with MSH6 showing the highest risks (ref. 82; Table 1). However, the higher range estimates may reflect reliance on data from clinical cancer genetic cohorts that are biased to include patients with family histories of cancer. Although Lynch syndrome is associated with a high cumulative lifetime risk of endometrial cancer, the relative rarity of the condition translates to an attributable fraction of only 5%.

The genome-wide association study approach has identified 17 risk loci for endometrial cancer, including 9 recently identified loci (83), which are modestly associated with risk (ORs, 0.8–1.4). Some risk loci are significant only for endometrioid cancers. Few rare variants have been identified through exome-wide association studies (84), but candidate gene studies (85, 86) have identified a number of SNPs in genes that may possibly affect risk.

Etiologic Heterogeneity

Important heterogeneity has been noted between type I (predominantly endometrioid adenocarcinomas with a hormonally driven etiology) and type II (mainly nonendometrioid malignancies that occur frequently among older and nonwhite women) cancers (see Tables 1 and 2). Several epidemiologic studies have found that type II cancers are less strongly linked to classic risk factors, such as obesity, nulliparity, and hormones (44, 87).

View this table:
Table 2.

Summary of associations of established risk factors with type and histology of endometrial cancer

Stronger relationships of hormonal, reproductive, and anthropometric risk factors have been found for endometrioid endometrial cancers compared with serous, clear cell, mucinous, or mixed epithelial tumors (44, 87–91). Furthermore, The Cancer Genome Atlas (TCGA) study has identified four molecular subtypes of endometrial cancer: polymerase ε (POLE) ultramutated, microsatellite instability hypermutated, copy-number low, and copy-number high clusters (92). A comprehensive evaluation of endometrial cancer risk factors according to TCGA subtype has not yet been conducted.

Biological Underpinnings of Identified Risk Factors

Estrogens are strongly related to risk (Table 1; refs. 93–95), with one study showing generalized uterotropic activity of both parent estrogens and metabolites (96). Circulating androgens, the main source of estrogens in postmenopausal women, have also been linked with increased risk (93–95, 97, 98). Consistent with an association between diabetes and endometrial cancer risk, insulin and c-peptide have been demonstrated to be elevated among women with endometrial cancer (99). Insulin-like growth factor 1 (IGF)-1 and the IGF-binding proteins are less consistently linked with risk (100, 101). Risk has also been related to circulating levels of inflammatory biomarkers (102) and with several obesity-related hormones (103).

Risk Prediction Models

Two risk prediction models, one developed in U.S.-based cohorts (104) and the other in a European cohort (105), demonstrated moderate discriminatory ability for established endometrial cancer risk factors (respective discrimination assessed by the area under the curve of 0.68 and 0.77). In the latter model, the addition of prediagnostic serum biomarkers only modestly (1.7%) increased discrimination (106).

Future Trends

Projection models indicate that endometrial cancer incidence will continue to rise, mainly as a consequence of rising obesity prevalence (7, 107). Changes in the distribution of other endometrial cancer risk factors also contribute to the projected growth in incidence, including increases in diabetes and metabolic syndrome (108, 109), declines in use of combination hormone therapy (5), and decreases in childbearing and smoking (110, 111). Moreover, hysterectomy for benign conditions has declined in recent decades, particularly among whites, contributing to more at-risk women (18, 112). In the next decade, mortality rates are also projected to increase (113).

Prevention

Primary prevention efforts focused on weight loss or use of medications are attractive prevention strategies. For high-risk patients, bariatric surgery is associated with a 44% reduced risk of developing endometrial cancer (114). Among Lynch syndrome patients, there is some evidence that oral contraceptive use may reduce risk (115).

Screening

Endometrial cancer screening is not recommended for women in the general population (116). Studies evaluating the use of endometrial biopsy and/or transvaginal ultrasound have generally shown low detection specificity (117). Nonetheless, the American Cancer Society recommends annual screening for Lynch syndrome patients with endometrial biopsy beginning at age 35 years. Development of early detection blood-based biomarkers is being explored (118).

Future Directions

Although considered an indolent tumor, the rapid increase in both endometrial cancer incidence and mortality warrants additional etiologic and prevention research. Although progress has been made in identifying risk factors for the most common endometrial cancer subtype, this has not translated into effective primary prevention strategies. Future efforts should be directed at reducing the prevalence of modifiable risk factors (e.g., obesity). Additional research is needed to identify risk factors for aggressive endometrial cancer subtypes, particularly among black women.

To favorably affect survival, research on screening modalities to identify endometrial cancer at early stages is needed. Currently, screening in the general population is not recommended, but efforts to identify high-risk women could be beneficial.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: A.S. Felix, L.A. Brinton

Development of methodology: A.S. Felix, L.A. Brinton

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A.S. Felix, L.A. Brinton

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A.S. Felix, L.A. Brinton

Writing, review, and/or revision of the manuscript: A.S. Felix, L.A. Brinton

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A.S. Felix, L.A. Brinton

Study supervision: A.S. Felix, L.A. Brinton

  • Received March 9, 2018.
  • Revision received April 7, 2018.
  • Accepted May 15, 2018.
  • Published first September 1, 2018.

References

  1. 1.↵
    1. Ferlay J,
    2. Soerjomataram I,
    3. Ervik M,
    4. Dikshit R,
    5. Eser S,
    6. Mathers C,
    7. et al.
    GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. [cited 2018 Apr 7]. Available from: http://globocan.iarc.fr/Default.aspx. Lyon, France: International Agency for Research on Cancer. 2013.
  2. 2.↵
    1. Siegel RL,
    2. Miller KD,
    3. Jemal A
    . Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Siegel RL,
    2. Miller KD,
    3. Jemal A
    . Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Torre LA,
    2. Islami F,
    3. Siegel RL,
    4. Ward EM,
    5. Jemal A
    . Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev 2017;26:444–57.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Wartko P,
    2. Sherman ME,
    3. Yang HP,
    4. Felix AS,
    5. Brinton LA,
    6. Trabert B
    . Recent changes in endometrial cancer trends among menopausal-age U.S. women. Cancer Epidemiol 2013;37:374–7.
    OpenUrl
  6. 6.↵
    1. Weiderpass E,
    2. Antoine J,
    3. Bray FI,
    4. Oh JK,
    5. Arbyn M
    . Trends in corpus uteri cancer mortality in member states of the European Union. Eur J Cancer 2014;50:1675–84.
    OpenUrl
  7. 7.↵
    1. Rahib L,
    2. Smith BD,
    3. Aizenberg R,
    4. Rosenzweig AB,
    5. Fleshman JM,
    6. Matrisian LM
    . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913–21.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Creasman WT,
    2. Odicino F,
    3. Maisonneuve P,
    4. Quinn MA,
    5. Beller U,
    6. Benedet JL,
    7. et al.
    Carcinoma of the corpus uteri. FIGO 26th Annual Report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006;95 Suppl 1:S105–43.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. DeSantis CE,
    2. Lin CC,
    3. Mariotto AB,
    4. Siegel RL,
    5. Stein KD,
    6. Kramer JL,
    7. et al.
    Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014;64:252–71.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Ueda SM,
    2. Kapp DS,
    3. Cheung MK,
    4. Shin JY,
    5. Osann K,
    6. Husain A,
    7. et al.
    Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 2008;198:218e1–6.
    OpenUrl
  11. 11.↵
    1. Creasman WT,
    2. Ali S,
    3. Mutch DG,
    4. Zaino RJ,
    5. Powell MA,
    6. Mannel RS,
    7. et al.
    Surgical-pathological findings in type 1 and 2 endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. Gynecol Oncol 2017;145:519–25.
    OpenUrl
  12. 12.↵
    1. Wright JD,
    2. Fiorelli J,
    3. Schiff PB,
    4. Burke WM,
    5. Kansler AL,
    6. Cohen CJ,
    7. et al.
    Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer 2009;115:1276–85.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Farley J,
    2. Risinger JI,
    3. Rose GS,
    4. Maxwell GL
    . Racial disparities in blacks with gynecologic cancers. Cancer 2007;110:234–43.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Allard JE,
    2. Maxwell GL
    . Race disparities between black and white women in the incidence, treatment, and prognosis of endometrial cancer. Cancer Control 2009;16:53–6.
    OpenUrlPubMed
  15. 15.↵
    1. Long B,
    2. Liu FW,
    3. Bristow RE
    . Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States. Gynecol Oncol 2013;130:652–9.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Collins Y,
    2. Holcomb K,
    3. Chapman-Davis E,
    4. Khabele D,
    5. Farley JH
    . Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology. Gynecol Oncol 2014;133:353–61.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Cote ML,
    2. Ruterbusch JJ,
    3. Olson SH,
    4. Lu K,
    5. Ali-Fehmi R
    . The growing burden of endometrial cancer: a major racial disparity affecting black women. Cancer Epidemiol Biomarkers Prev 2015;24:1407–15.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Jamison PM,
    2. Noone AM,
    3. Ries LA,
    4. Lee NC,
    5. Edwards BK
    . Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol Biomarkers Prev 2013;22:233–41.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Cote ML,
    2. Alhajj T,
    3. Ruterbusch JJ,
    4. Bernstein L,
    5. Brinton LA,
    6. Blot WJ,
    7. et al.
    Risk factors for endometrial cancer in black and white women: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2). Cancer Causes Control 2015;26:287–96.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Morris AM,
    2. Rhoads KF,
    3. Stain SC,
    4. Birkmeyer JD
    . Understanding racial disparities in cancer treatment and outcomes. J Am Coll Surg 2010;211:105–13.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Setiawan VW,
    2. Pike MC,
    3. Kolonel LN,
    4. Nomura AM,
    5. Goodman MT,
    6. Henderson BE
    . Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study. Am J Epidemiol 2007;165:262–70.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Bhaskaran K,
    2. Douglas I,
    3. Forbes H,
    4. dos-Santos-Silva I,
    5. Leon DA,
    6. Smeeth L
    . Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 2014;384:755–65.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Onstad MA,
    2. Schmandt RE,
    3. Lu KH
    . Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol 2016;34:4225–30.
    OpenUrl
  24. 24.↵
    1. Ju W,
    2. Kim HJ,
    3. Hankinson SE,
    4. De Vivo I,
    5. Cho E
    . Prospective study of body fat distribution and the risk of endometrial cancer. Cancer Epidemiol 2015;39:567–70.
    OpenUrl
  25. 25.↵
    1. Tsilidis KK,
    2. Kasimis JC,
    3. Lopez DS,
    4. Ntzani EE,
    5. Ioannidis JP
    . Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 2015;350:g7607.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Liao C,
    2. Zhang D,
    3. Mungo C,
    4. Andrew Tompkins D,
    5. Zeidan AM
    . Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. Gynecol Oncol 2014;135:163–71.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Aune D,
    2. Sen A,
    3. Vatten LJ
    . Hypertension and the risk of endometrial cancer: a systematic review and meta-analysis of case-control and cohort studies. Sci Rep 2017;7:44808.
    OpenUrl
  28. 28.↵
    1. Barry JA,
    2. Azizia MM,
    3. Hardiman PJ
    . Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2014;20:748–58.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Esposito K,
    2. Chiodini P,
    3. Capuano A,
    4. Bellastella G,
    5. Maiorino MI,
    6. Giugliano D
    . Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine 2014;45:28–36.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Dossus L,
    2. Allen N,
    3. Kaaks R,
    4. Bakken K,
    5. Lund E,
    6. Tjonneland A,
    7. et al.
    Reproductive risk factors and endometrial cancer: the European prospective investigation into cancer and nutrition. Int J Cancer 2010;127:442–51.
    OpenUrlPubMed
  31. 31.↵
    1. Wu QJ,
    2. Li YY,
    3. Tu C,
    4. Zhu J,
    5. Qian KQ,
    6. Feng TB,
    7. et al.
    Parity and endometrial cancer risk: a meta-analysis of epidemiological studies. Sci Rep 2015;5:14243.
    OpenUrl
  32. 32.↵
    1. Yang HP,
    2. Cook LS,
    3. Weiderpass E,
    4. Adami HO,
    5. Anderson KE,
    6. Cai H,
    7. et al.
    Infertility and incident endometrial cancer risk: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2). Br J Cancer 2015;112:925–33.
    OpenUrl
  33. 33.↵
    1. Gong TT,
    2. Wang YL,
    3. Ma XX
    . Age at menarche and endometrial cancer risk: a dose-response meta-analysis of prospective studies. Sci Rep 2015;5:14051.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Yang HP,
    2. Murphy KR,
    3. Pfeiffer RM,
    4. George N,
    5. Garcia-Closas M,
    6. Lissowska J,
    7. et al.
    Lifetime number of ovulatory cycles and risks of ovarian and endometrial cancer among postmenopausal women. Am J Epidemiol 2016;183:800–14.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Jordan SJ,
    2. Na R,
    3. Johnatty SE,
    4. Wise LA,
    5. Adami HO,
    6. Brinton LA,
    7. et al.
    Breastfeeding and endometrial cancer risk: an analysis from the epidemiology of endometrial cancer consortium. Obstet Gynecol 2017;129:1059–67.
    OpenUrl
  36. 36.↵
    1. Zhan B,
    2. Liu X,
    3. Li F,
    4. Zhang D
    . Breastfeeding and the incidence of endometrial cancer: a meta-analysis. Oncotarget 2015;6:38398–409.
    OpenUrl
  37. 37.↵
    1. Felix AS,
    2. Gaudet MM,
    3. La Vecchia C,
    4. Nagle CM,
    5. Shu XO,
    6. Weiderpass E,
    7. et al.
    Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium. Int J Cancer 2015;136:E410–22.
    OpenUrl
  38. 38.↵
    1. Beining RM,
    2. Dennis LK,
    3. Smith EM,
    4. Dokras A
    . Meta-analysis of intrauterine device use and risk of endometrial cancer. Ann Epidemiol 2008;18:492–9.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Beral V,
    2. Bull D,
    3. Reeves G,
    4. Million Women Study C
    . Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543–51.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Lacey JV Jr.,
    2. Sherman ME,
    3. Rush BB,
    4. Ronnett BM,
    5. Ioffe OB,
    6. Duggan MA,
    7. et al.
    Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 2010;28:788–92.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Razavi P,
    2. Pike MC,
    3. Horn-Ross PL,
    4. Templeman C,
    5. Bernstein L,
    6. Ursin G
    . Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol Biomarkers Prev 2010;19:475–83.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Chlebowski RT,
    2. Anderson GL,
    3. Sarto GE,
    4. Haque R,
    5. Runowicz CD,
    6. Aragaki AK,
    7. et al.
    Continuous combined estrogen plus progestin and endometrial cancer: the Women's Health Initiative Randomized Trial. J Natl Cancer Inst 2016;108.
  43. 43.↵
    1. Trabert B,
    2. Wentzensen N,
    3. Yang HP,
    4. Sherman ME,
    5. Hollenbeck AR,
    6. Park Y,
    7. et al.
    Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer 2013;132:417–26.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Brinton LA,
    2. Felix AS,
    3. McMeekin DS,
    4. Creasman WT,
    5. Sherman ME,
    6. Mutch D,
    7. et al.
    Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol 2013;129:277–84.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Cuzick J,
    2. Sestak I,
    3. Bonanni B,
    4. Costantino JP,
    5. Cummings S,
    6. DeCensi A,
    7. et al.
    Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013;381:1827–34.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Yang HP,
    2. Brinton LA,
    3. Platz EA,
    4. Lissowska J,
    5. Lacey JV Jr.,
    6. Sherman ME,
    7. et al.
    Active and passive cigarette smoking and the risk of endometrial cancer in Poland. Eur J Cancer 2010;46:690–6.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Zhou B,
    2. Yang L,
    3. Sun Q,
    4. Cong R,
    5. Gu H,
    6. Tang N,
    7. et al.
    Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med 2008;121:501–8e3.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Moore SC,
    2. Gierach GL,
    3. Schatzkin A,
    4. Matthews CE
    . Physical activity, sedentary behaviours, and the prevention of endometrial cancer. Br J Cancer 2010;103:933–8.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Schmid D,
    2. Behrens G,
    3. Keimling M,
    4. Jochem C,
    5. Ricci C,
    6. Leitzmann M
    . A systematic review and meta-analysis of physical activity and endometrial cancer risk. Eur J Epidemiol 2015;30:397–412.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Keum N,
    2. Ju W,
    3. Lee DH,
    4. Ding EL,
    5. Hsieh CC,
    6. Goodman JE,
    7. et al.
    Leisure-time physical activity and endometrial cancer risk: dose-response meta-analysis of epidemiological studies. Int J Cancer 2014;135:682–94.
    OpenUrlPubMed
  51. 51.↵
    1. Biel RK,
    2. Csizmadi I,
    3. Cook LS,
    4. Courneya KS,
    5. Magliocco AM,
    6. Friedenreich CM
    . Risk of endometrial cancer in relation to individual nutrients from diet and supplements. Public Health Nutr 2011;14:1948–60.
    OpenUrlPubMed
  52. 52.↵
    1. Bandera EV,
    2. Kushi LH,
    3. Moore DF,
    4. Gifkins DM,
    5. McCullough ML
    . Fruits and vegetables and endometrial cancer risk: a systematic literature review and meta-analysis. Nutr Cancer 2007;58:6–21.
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. Prentice RL,
    2. Thomson CA,
    3. Caan B,
    4. Hubbell FA,
    5. Anderson GL,
    6. Beresford SA,
    7. et al.
    Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst 2007;99:1534–43.
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. Zhao J,
    2. Lyu C,
    3. Gao J,
    4. Du L,
    5. Shan B,
    6. Zhang H,
    7. et al.
    Dietary fat intake and endometrial cancer risk: a dose response meta-analysis. Medicine (Baltimore) 2016;95:e4121.
    OpenUrl
  55. 55.↵
    1. Li X,
    2. Zhao J,
    3. Li P,
    4. Gao Y
    . Dairy products intake and endometrial cancer risk: a meta-analysis of observational studies. Nutrients 2017;10.
  56. 56.↵
    1. Lafranconi A,
    2. Micek A,
    3. Galvano F,
    4. Rossetti S,
    5. Del Pup L,
    6. Berretta M,
    7. et al.
    Coffee decreases the risk of endometrial cancer: a dose-response meta-analysis of prospective cohort studies. Nutrients 2017;9.
  57. 57.↵
    1. Zhou Q,
    2. Li H,
    3. Zhou JG,
    4. Ma Y,
    5. Wu T,
    6. Ma H
    . Green tea, black tea consumption and risk of endometrial cancer: a systematic review and meta-analysis. Arch Gynecol Obstet 2016;293:143–55.
    OpenUrl
  58. 58.↵
    1. Zhou Q,
    2. Guo P,
    3. Li H,
    4. Chen XD
    . Does alcohol consumption modify the risk of endometrial cancer? A dose-response meta-analysis of prospective studies. Arch Gynecol Obstet 2017;295:467–79.
    OpenUrl
  59. 59.↵
    1. Tang YL,
    2. Zhu LY,
    3. Li Y,
    4. Yu J,
    5. Wang J,
    6. Zeng XX,
    7. et al.
    Metformin use is associated with reduced incidence and improved survival of endometrial cancer: a meta-analysis. BioMed Res Int 2017;2017:5905384.
    OpenUrl
  60. 60.↵
    1. Verdoodt F,
    2. Friis S,
    3. Dehlendorff C,
    4. Albieri V,
    5. Kjaer SK
    . Non-steroidal anti-inflammatory drug use and risk of endometrial cancer: a systematic review and meta-analysis of observational studies. Gynecol Oncol 2016;140:352–8.
    OpenUrl
  61. 61.↵
    1. Weiderpass E,
    2. Pukkala E,
    3. Vasama-Neuvonen K,
    4. Kauppinen T,
    5. Vainio H,
    6. Paakkulainen H,
    7. et al.
    Occupational exposures and cancers of the endometrium and cervix uteri in Finland. Am J Ind Med 2001;39:572–80.
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Wernli KJ,
    2. Ray RM,
    3. Gao DL,
    4. Fitzgibbons ED,
    5. Camp JE,
    6. Astrakianakis G,
    7. et al.
    Occupational risk factors for endometrial cancer among textile workers in Shanghai, China. Am J Ind Med 2008;51:673–9.
    OpenUrlPubMed
  63. 63.↵
    1. Karageorgi S,
    2. Gates MA,
    3. Hankinson SE,
    4. De Vivo I
    . Perineal use of talcum powder and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2010;19:1269–75.
    OpenUrlAbstract/FREE Full Text
  64. 64.↵
    1. Neill AS,
    2. Nagle CM,
    3. Spurdle AB,
    4. Webb PM
    . Use of talcum powder and endometrial cancer risk. Cancer Causes Control 2012;23:513–9.
    OpenUrlCrossRefPubMed
  65. 65.↵
    1. Crawford L,
    2. Reeves KW,
    3. Luisi N,
    4. Balasubramanian R,
    5. Sturgeon SR
    . Perineal powder use and risk of endometrial cancer in postmenopausal women. Cancer Causes Control 2012;23:1673–80.
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. Fortuny J,
    2. Sima C,
    3. Bayuga S,
    4. Wilcox H,
    5. Pulick K,
    6. Faulkner S,
    7. et al.
    Risk of endometrial cancer in relation to medical conditions and medication use. Cancer Epidemiol Biomarkers Prev 2009;18:1448–56.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. Poole EM,
    2. Lin WT,
    3. Kvaskoff M,
    4. De Vivo I,
    5. Terry KL,
    6. Missmer SA
    . Endometriosis and risk of ovarian and endometrial cancers in a large prospective cohort of U.S. nurses. Cancer Causes Control 2017;28:437–45.
    OpenUrl
  68. 68.↵
    1. Morimoto LM,
    2. Newcomb PA,
    3. Hampton JM,
    4. Trentham-Dietz A
    . Cholecystectomy and endometrial cancer: a marker of long-term elevated estrogen exposure? Int J Gynecol Cancer 2006;16:1348–53.
    OpenUrlCrossRefPubMed
  69. 69.↵
    1. Lin CF,
    2. Chan HL,
    3. Hsieh YH,
    4. Liang HY,
    5. Chiu WC,
    6. Huang KY,
    7. et al.
    Endometrial cancer and antidepressants: a nationwide population-based study. Medicine 2016;95:e4178.
    OpenUrl
  70. 70.↵
    1. Sperling CD,
    2. Verdoodt F,
    3. Friis S,
    4. Dehlendorff C,
    5. Kjaer SK
    . Statin use and risk of endometrial cancer: a nationwide registry-based case-control study. Acta Obstet Gynecol Scand 2017;96:144–9.
    OpenUrl
  71. 71.↵
    1. Ding YY,
    2. Yao P,
    3. Verma S,
    4. Han ZK,
    5. Hong T,
    6. Zhu YQ,
    7. et al.
    Use of acetaminophen and risk of endometrial cancer: evidence from observational studies. Oncotarget 2017;8:34643–51.
    OpenUrl
  72. 72.↵
    1. Weiderpass E,
    2. Adami HO,
    3. Baron JA,
    4. Wicklund-Glynn A,
    5. Aune M,
    6. Atuma S,
    7. et al.
    Organochlorines and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2000;9:487–93.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    1. Winer I,
    2. Lehman A,
    3. Wactawski-Wende J,
    4. Robinson R,
    5. Simon M,
    6. Cote M
    . Tubal ligation and risk of endometrial cancer: findings from the Women's Health Initiative. Int J Gynecol Cancer 2016;26:464–71.
    OpenUrl
  74. 74.↵
    1. Abel EL,
    2. Hendrix SL,
    3. McNeeley GS,
    4. O'Leary ES,
    5. Mossavar-Rahmani Y,
    6. Johnson SR,
    7. et al.
    Use of electric blankets and association with prevalence of endometrial cancer. Eur J Cancer Prev 2007;16:243–50.
    OpenUrlPubMed
  75. 75.↵
    1. Win AK,
    2. Reece JC,
    3. Ryan S
    . Family history and risk of endometrial cancer: a systematic review and meta-analysis. Obstet Gynecol 2015;125:89–98.
    OpenUrlCrossRefPubMed
  76. 76.↵
    1. Johnatty SE,
    2. Tan YY,
    3. Buchanan DD,
    4. Bowman M,
    5. Walters RJ,
    6. Obermair A,
    7. et al.
    Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling. Gynecol Oncol 2017;147:381–7.
    OpenUrl
  77. 77.↵
    1. Dowty JG,
    2. Win AK,
    3. Buchanan DD,
    4. Lindor NM,
    5. Macrae FA,
    6. Clendenning M,
    7. et al.
    Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat 2013;34:490–7.
    OpenUrlCrossRefPubMed
  78. 78.↵
    1. Bonadona V,
    2. Bonaiti B,
    3. Olschwang S,
    4. Grandjouan S,
    5. Huiart L,
    6. Longy M,
    7. et al.
    Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011;305:2304–10.
    OpenUrlCrossRefPubMed
  79. 79.↵
    1. Ramsoekh D,
    2. Wagner A,
    3. van Leerdam ME,
    4. Dooijes D,
    5. Tops CM,
    6. Steyerberg EW,
    7. et al.
    Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management. Hered Cancer Clin Pract 2009;7:17.
    OpenUrlCrossRefPubMed
  80. 80.↵
    1. ten Broeke SW,
    2. Brohet RM,
    3. Tops CM,
    4. van der Klift HM,
    5. Velthuizen ME,
    6. Bernstein I,
    7. et al.
    Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. J Clin Oncol 2015;33:319–25.
    OpenUrlAbstract/FREE Full Text
  81. 81.↵
    1. Kempers MJ,
    2. Kuiper RP,
    3. Ockeloen CW,
    4. Chappuis PO,
    5. Hutter P,
    6. Rahner N,
    7. et al.
    Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 2011;12:49–55.
    OpenUrlCrossRefPubMed
  82. 82.↵
    1. Sijmons RH,
    2. Hofstra RM
    . Review: clinical aspects of hereditary DNA mismatch repair gene mutations. DNA Repair 2016;38:155–62.
    OpenUrl
  83. 83.↵
    1. O'Mara TA,
    2. Glubb DM,
    3. Amant F,
    4. Annibali D,
    5. Ashton K,
    6. Attia J,
    7. et al.
    Identification of nine new susceptibility loci for endometrial cancer. Nat Comm 2018;9:3166.
    OpenUrl
  84. 84.↵
    1. Chen MM,
    2. Crous-Bou M,
    3. Setiawan VW,
    4. Prescott J,
    5. Olson SH,
    6. Wentzensen N,
    7. et al.
    Exome-wide association study of endometrial cancer in a multiethnic population. PLoS One 2014;9:e97045.
    OpenUrlCrossRefPubMed
  85. 85.↵
    1. Meyer LA,
    2. Westin SN,
    3. Lu KH,
    4. Milam MR
    . Genetic polymorphisms and endometrial cancer risk. Expert Rev Anticancer Ther 2008;8:1159–67.
    OpenUrlPubMed
  86. 86.↵
    1. Spurdle AB,
    2. Thompson DJ,
    3. Ahmed S,
    4. Ferguson K,
    5. Healey CS,
    6. O'Mara T,
    7. et al.
    Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nature genetics 2011;43:451–4.
    OpenUrlCrossRefPubMed
  87. 87.↵
    1. Setiawan VW,
    2. Yang HP,
    3. Pike MC,
    4. McCann SE,
    5. Yu H,
    6. Xiang YB,
    7. et al.
    Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 2013;31:2607–18.
    OpenUrlAbstract/FREE Full Text
  88. 88.↵
    1. Sherman ME,
    2. Sturgeon S,
    3. Brinton LA,
    4. Potischman N,
    5. Kurman RJ,
    6. Berman ML,
    7. et al.
    Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol 1997;10:963–8.
    OpenUrlPubMed
  89. 89.↵
    1. Felix AS,
    2. Weissfeld JL,
    3. Stone RA,
    4. Bowser R,
    5. Chivukula M,
    6. Edwards RP,
    7. et al.
    Factors associated with type I and type II endometrial cancer. Cancer Causes Control 2010;21:1851–6.
    OpenUrlCrossRefPubMed
  90. 90.↵
    1. Yang HP,
    2. Wentzensen N,
    3. Trabert B,
    4. Gierach GL,
    5. Felix AS,
    6. Gunter MJ,
    7. et al.
    Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP Diet and Health Study. Am J Epidemiol 2013;177:142–51.
    OpenUrlCrossRefPubMed
  91. 91.↵
    1. Trabert B,
    2. Wentzensen N,
    3. Felix AS,
    4. Yang HP,
    5. Sherman ME,
    6. Brinton LA
    . Metabolic syndrome and risk of endometrial cancer in the united states: a study in the SEER-medicare linked database. Cancer Epidemiol Biomarkers Prev 2015;24:261–7.
    OpenUrlAbstract/FREE Full Text
  92. 92.↵
    1. Kandoth C,
    2. Schultz N,
    3. Cherniack AD,
    4. Akbani R,
    5. Liu Y,
    6. et al.
    Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67–73.
    OpenUrlCrossRefPubMed
  93. 93.↵
    1. Allen NE,
    2. Key TJ,
    3. Dossus L,
    4. Rinaldi S,
    5. Cust A,
    6. Lukanova A,
    7. et al.
    Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2008;15:485–97.
    OpenUrlAbstract/FREE Full Text
  94. 94.↵
    1. Lukanova A,
    2. Lundin E,
    3. Micheli A,
    4. Arslan A,
    5. Ferrari P,
    6. Rinaldi S,
    7. et al.
    Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004;108:425–32.
    OpenUrlCrossRefPubMed
  95. 95.↵
    1. Zeleniuch-Jacquotte A,
    2. Akhmedkhanov A,
    3. Kato I,
    4. Koenig KL,
    5. Shore RE,
    6. Kim MY,
    7. et al.
    Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 2001;84:975–81.
    OpenUrlCrossRefPubMed
  96. 96.↵
    1. Brinton LA,
    2. Trabert B,
    3. Anderson GL,
    4. Falk RT,
    5. Felix AS,
    6. Fuhrman BJ,
    7. et al.
    Serum estrogens and estrogen metabolites and endometrial cancer risk among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2016;25:1081–9.
    OpenUrlAbstract/FREE Full Text
  97. 97.
    1. Potischman N,
    2. Hoover RN,
    3. Brinton LA,
    4. Siiteri P,
    5. Dorgan JF,
    6. Swanson CA,
    7. et al.
    Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996;88:1127–35.
    OpenUrlCrossRefPubMed
  98. 98.
    1. Clendenen TV,
    2. Hertzmark K,
    3. Koenig KL,
    4. Lundin E,
    5. Rinaldi S,
    6. Johnson T,
    7. et al.
    Premenopausal circulating androgens and risk of endometrial cancer: results of a prospective study. Horm Cancer 2016;7:178–87.
    OpenUrl
  99. 99.↵
    1. Hernandez AV,
    2. Pasupuleti V,
    3. Benites-Zapata VA,
    4. Thota P,
    5. Deshpande A,
    6. Perez-Lopez FR
    . Insulin resistance and endometrial cancer risk: a systematic review and meta-analysis. Eur J Cancer 2015;51:2747–58.
    OpenUrl
  100. 100.↵
    1. Gunter MJ,
    2. Hoover DR,
    3. Yu H,
    4. Wassertheil-Smoller S,
    5. Manson JE,
    6. Li J,
    7. et al.
    A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2008;17:921–9.
    OpenUrlAbstract/FREE Full Text
  101. 101.↵
    1. Zhan Y,
    2. Wang J,
    3. Ma Y,
    4. Liu Z,
    5. Xu H,
    6. Lu S,
    7. et al.
    Serum insulin-like, growth factor binding protein-related protein 1 (IGFBP-rP1) and endometrial cancer risk in Chinese women. Int J Cancer 2013;132:411–6.
    OpenUrlPubMed
  102. 102.↵
    1. Trabert B,
    2. Eldridge RC,
    3. Pfeiffer RM,
    4. Shiels MS,
    5. Kemp TJ,
    6. Guillemette C,
    7. et al.
    Pre-diagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Int J Cancer 2017;140:600–10.
    OpenUrl
  103. 103.↵
    1. Gong TT,
    2. Wu QJ,
    3. Wang YL,
    4. Ma XX
    . Circulating adiponectin, leptin and adiponectin-leptin ratio and endometrial cancer risk: evidence from a meta-analysis of epidemiologic studies. Int J Cancer 2015;137:1967–78.
    OpenUrl
  104. 104.↵
    1. Pfeiffer RM,
    2. Park Y,
    3. Kreimer AR,
    4. Lacey JV Jr.,
    5. Pee D,
    6. Greenlee RT,
    7. et al.
    Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med 2013;10:e1001492.
    OpenUrlCrossRefPubMed
  105. 105.↵
    1. Husing A,
    2. Dossus L,
    3. Ferrari P,
    4. Tjonneland A,
    5. Hansen L,
    6. Fagherazzi G,
    7. et al.
    An epidemiological model for prediction of endometrial cancer risk in Europe. Eur J Epidemiol 2016;31:51–60.
    OpenUrl
  106. 106.↵
    1. Fortner RT,
    2. Husing A,
    3. Kuhn T,
    4. Konar M,
    5. Overvad K,
    6. Tjonneland A,
    7. et al.
    Endometrial cancer risk prediction including serum-based biomarkers: results from the EPIC cohort. Int J Cancer 2017;140:1317–23.
    OpenUrl
  107. 107.↵
    1. Sheikh MA,
    2. Althouse AD,
    3. Freese KE,
    4. Soisson S,
    5. Edwards RP,
    6. Welburn S,
    7. et al.
    USA endometrial cancer projections to 2030: should we be concerned? Future Oncol 2014;10:2561–8.
    OpenUrlPubMed
  108. 108.↵
    1. Menke A,
    2. Casagrande S,
    3. Geiss L,
    4. Cowie CC
    . Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA 2015;314:1021–9.
    OpenUrlCrossRefPubMed
  109. 109.↵
    1. Mozumdar A,
    2. Liguori G
    . Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006. Diabetes Care 2011;34:216–9.
    OpenUrlAbstract/FREE Full Text
  110. 110.↵
    1. Curtin SC,
    2. Abma JC,
    3. Ventura SJ,
    4. Henshaw SK
    . Pregnancy rates for U.S. women continue to drop. NCHS Data Brief 2013:1–8.
  111. 111.
    1. Jamal A,
    2. Agaku I,
    3. O'Connor E,
    4. King B,
    5. Kenemer J,
    6. Neff L
    . Current cigarette smoking among adults—United States, 2005–2013. MMWR Morb Mortal Wkly Rep 2014;63:1108–12.
    OpenUrlPubMed
  112. 112.↵
    1. Wright JD,
    2. Herzog TJ,
    3. Tsui J,
    4. Ananth CV,
    5. Lewin SN,
    6. Lu YS,
    7. et al.
    Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol 2013;122(2 Pt 1):233–41.
    OpenUrlCrossRefPubMed
  113. 113.↵
    1. Jemal A,
    2. Ward EM,
    3. Johnson CJ,
    4. Cronin KA,
    5. Ma J,
    6. Ryerson B,
    7. et al.
    Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst 2017;109.
  114. 114.↵
    1. Anveden A,
    2. Taube M,
    3. Peltonen M,
    4. Jacobson P,
    5. Andersson-Assarsson JC,
    6. Sjoholm K,
    7. et al.
    Long-term incidence of female-specific cancer after bariatric surgery or usual care in the Swedish Obese Subjects Study. Gynecol Oncol 2017;145:224–9.
    OpenUrl
  115. 115.↵
    1. Lu KH,
    2. Loose DS,
    3. Yates MS,
    4. Nogueras-Gonzalez GM,
    5. Munsell MF,
    6. Chen LM,
    7. et al.
    Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome. Cancer Prev Res 2013;6:774–81.
    OpenUrlAbstract/FREE Full Text
  116. 116.↵
    1. Jacobs I,
    2. Gentry-Maharaj A,
    3. Burnell M,
    4. Manchanda R,
    5. Singh N,
    6. Sharma A,
    7. et al.
    Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol 2011;12:38–48.
    OpenUrlCrossRefPubMed
  117. 117.↵
    1. Sonoda Y,
    2. Barakat RR
    . Screening and the prevention of gynecologic cancer: endometrial cancer. Best Pract Res Clin Obstet Gynaecol 2006;20:363–77.
    OpenUrlPubMed
  118. 118.↵
    1. Martinez-Garcia E,
    2. Lopez-Gil C,
    3. Campoy I,
    4. Vallve J,
    5. Coll E,
    6. Cabrera S,
    7. et al.
    Advances in endometrial cancer protein biomarkers for use in the clinic. Expert Rev Proteomics 2018;15:81–99.
    OpenUrl
Back to top
Cancer Epidemiology Biomarkers & Prevention: 27 (9)
September 2018
Volume 27, Issue 9

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Email Article
Citation Tools
Cancer Progress and Priorities: Uterine Cancer
Ashley S. Felix and Louise A. Brinton
Cancer Epidemiol Biomarkers Prev September 1 2018 (27) (9) 985-994; DOI: 10.1158/1055-9965.EPI-18-0264
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement